SCHEMBL275702

SCHEMBL275702

CC(C)(C)[Si](C)(C)Oc1cc(Cl)ccc1C=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.44
ERN1 O75460 4/20 0.39
PTPN1 P18031 1/20 0.38
ALDH1A1 P00352 5/20 0.37
HPGD P15428 2/20 0.36
SRC P12931 1/20 0.36
TRPV4 Q9HBA0 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.33
CA12 O43570 2/20 0.33
CA1 P00915 2/20 0.33
CA9 Q16790 2/20 0.33
LMNA P02545 2/20 0.33
KDM4E B2RXH2 2/20 0.32
MAPT P10636 2/20 0.32
POLB P06746 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
MEN1 O00255 1/20 0.32
NPC1 O15118 1/20 0.32
TP53 P04637 1/20 0.32
NFKB1 P19838 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL278950 0.88 ERN1 (0.42) TDP1ERN1PTPN1ALDH1A1HPGD
SCHEMBL19810818 0.83 ALDH1A1 (0.49) ERN1ALDH1A1CA12CA1CA9
SCHEMBL14679006 0.83 ERN1 (0.40) ERN1PTPN1ALDH1A1HPGDCA12
SCHEMBL17786204 0.83 ALDH1A1 (0.40) ERN1ALDH1A1HPGDSRCSMN1; SMN2
SCHEMBL6902425 0.81 PTPN1 (0.38) ERN1PTPN1ALDH1A1HPGDSMN1; SMN2
SCHEMBL275754 0.81 ERN1 (0.39) TDP1ERN1ALDH1A1CA12CA1
SCHEMBL2458060 0.81 KMT2A (0.33) TDP1ALDH1A1CA12CA1CA9
SCHEMBL6093144 0.78 TDP1 (0.55) TDP1ERN1PTPN1ALDH1A1HPGD
SCHEMBL29722800 0.77 ALDH1A1 (0.48) TDP1ERN1ALDH1A1HPGDSRC
SCHEMBL1201100 0.77 ALDH1A1 (0.48) TDP1ERN1ALDH1A1HPGDSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107001309-B Bis (sulfonamide) derivatives and their use as MPGES inhibitors 格辛塔制药公司 2021-03-05 CN disclosed
EP-3224253-B1 BIS (SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS GESYNTA PHARMA AB (SE) 2019-10-30 EP disclosed
US-10227296-B2 Bis(sulfonamide) derivatives and their use as mPGES inhibitors Arcturum Real Estate AB (SE) 2019-03-12 US disclosed
US-10227296-B2 Bis(sulfonamide) derivatives and their use as mPGES inhibitors Arcturum Real Estate AB (SE) 2019-03-12 US disclosed
US-10081614-B2 Bis(sulfonamide) derivatives and their use as mPGES inhibitors ACTURUM REAL ESTATE AB (SE) 2018-09-25 US disclosed
US-20180002278-A1 BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS ACTURUM REAL ESTATE AB (SE) 2018-01-04 US disclosed
US-20180002278-A1 BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS ACTURUM REAL ESTATE AB (SE) 2018-01-04 US disclosed
US-20170313672-A1 BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS GESYNTA PHARMA AB (SE) 2017-11-02 US disclosed
US-20170313672-A1 BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS GESYNTA PHARMA AB (SE) 2017-11-02 US disclosed
US-20170313672-A1 BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS GESYNTA PHARMA AB (SE) 2017-11-02 US disclosed
EP-3224253-A1 BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS Acturum Real Estate AB (SE) 2017-10-04 EP disclosed
EP-3224241-A1 BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS Acturum Real Estate AB (SE) 2017-10-04 EP disclosed
WO-2016085391-A1 BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS Acturum Life Science AB (SE) 2016-06-02 WO disclosed
WO-2016085392-A1 BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS Acturum Life Science AB (SE) 2016-06-02 WO disclosed
WO-2016085391-A1 BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS Acturum Life Science AB (SE) 2016-06-02 WO disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT TDP1 3097/4885ERN1 2608/4885PTPN1 2799/4885
US-10227296-B2 Bis(sulfonamide) derivatives and their use as mPGES inhibitors PTGES, PTGS1, PTGES2 TDP1 2289/4885ERN1 1744/4885PTPN1 859/4885
US-10081614-B2 Bis(sulfonamide) derivatives and their use as mPGES inhibitors PTGES, PTGS1, PTGES2 TDP1 2289/4885ERN1 1744/4885PTPN1 859/4885
US-20170313672-A1 BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS PTGES, PTGS1, PTGES2 TDP1 2289/4885ERN1 1744/4885PTPN1 859/4885
US-20180002278-A1 BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS PTGES, PTGS1, PTGES2 TDP1 2289/4885ERN1 1744/4885PTPN1 859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.